• Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, said two leading health insurers in Switzerland agreed to fully reimburse the cost of Scenesse (afamelanotide 16-mg implant) for erythropoietic protoporphyria, a rare disease characterized by severe phototoxicity.